{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:50:24Z","timestamp":1794639024414,"version":"4.9.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":1155,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1111\/j.1469-0691.2011.03630.x","type":"journal-article","created":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T22:56:23Z","timestamp":1310511383000},"page":"1478-1483","source":"Crossref","is-referenced-by-count":358,"title":["Leishmaniasis chemotherapy\u2014challenges and opportunities"],"prefix":"10.1016","volume":"17","author":[{"given":"S.L.","family":"Croft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Olliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2011.03630.x_bib1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop Med Int Health"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","article-title":"Chemotherapy in the treatment and control of leishmaniasis","volume":"61","author":"Alvar","year":"2006","journal-title":"Adv Parasitol"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib3","first-page":"388","article-title":"Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya","volume":"79","author":"Moore","year":"2001","journal-title":"Bull World Health Org"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single\u2010dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib6","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1371\/journal.pntd.0000818","article-title":"Cost\u2010effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent","volume":"4","author":"Meheus","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib7","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib8","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(87)90543-0","article-title":"The activity of alkyl phosphorylcholines and related derivatives againstLeishmania donovani","volume":"36","author":"Croft","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis","volume":"196","author":"Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/QCO.0b013e32833fca9d","article-title":"Drug combinations for visceral leishmaniasis","volume":"23","author":"Olliaro","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/AAC.50.1.73-79.2006","article-title":"In vitro andin vivo interactions between miltefosine and other antileishmanial drugs","volume":"50","author":"Seifert","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib13","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","article-title":"New treatment approach in Indian visceral leishmaniasis: single\u2010dose liposomal amphotericin B followed by short\u2010course oral miltefosine","volume":"47","author":"Sundar","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short\u2010course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open\u2010label, non\u2010inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib15","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericin B (ambisome) for visceral leishmaniasis in endemic developing countries","volume":"76","author":"Berman","year":"1998","journal-title":"Bull World Health Organ"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib16","doi-asserted-by":"crossref","first-page":"e709","DOI":"10.1371\/journal.pntd.0000709","article-title":"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open\u2010label, randomized trial","volume":"4","author":"Hailu","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib17","first-page":"10","article-title":"PKDL \u2013 a drug related phenomenon?","volume":"128","author":"Croft","year":"2008","journal-title":"Indian J Med Res"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2133.2011.10402.x","article-title":"Miltefosine as an effective choice in the treatment of post\u2010kala\u2010azar dermal leishmaniasis","volume":"165","author":"Ramesh","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trstmh.2007.08.006","article-title":"Immunochemotherapy of persistent post\u2010kala\u2010azar dermal leishmaniasis: a novel approach to treatment","volume":"102","author":"Musa","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trstmh.2009.07.026","article-title":"Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration","volume":"104","author":"Musa","year":"2010","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2006.04.001","article-title":"Mechanisms of experimental resistance of leishmania to miltefosine: implications for clinical use","volume":"9","author":"Perez\u2010Victoria","year":"2006","journal-title":"Drug Resist Updat"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib23","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4269\/ajtmh.2005.73.1005","article-title":"A phase II dose\u2010ranging study of sitamaquine for the treatment of visceral leishmaniasis in India","volume":"73","author":"Jha","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4269\/ajtmh.2005.73.871","article-title":"A phase II dose\u2010increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya","volume":"73","author":"Wasunna","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib25","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4269\/ajtmh.2011.10-0409","article-title":"Oral sitamaquine pharmacokinetics with or without food, and safety and efficacy for the treatment of visceral leishmaniasis","volume":"84","author":"Sundar","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trstmh.2010.11.004","article-title":"Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis","volume":"105","author":"Kshirsagar","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib27","first-page":"538","article-title":"Topical treatment for cutaneous leishmaniasis","volume":"3","author":"Garnier","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0190-9622(92)70175-F","article-title":"Topical treatment of old world cutaneous leishmaniasis caused byLeishmania major: a double\u2010blind control study","volume":"27","author":"El\u2010On","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib29","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1371\/journal.pntd.0000432","article-title":"Wr279,396, a third generation aminoglycoside ointment for the treatment ofLeishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study","volume":"3","author":"Ben Salah","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib30","first-page":"353","article-title":"Treatment of cutaneous leishmaniasis with aminosidine(paromomycin) ointment: double\u2010blind, randomized trial in the Islamic Republic of Iran","volume":"81","author":"Asilian","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib31","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4269\/ajtmh.2005.73.272","article-title":"The sensitivity of clinical isolates of leishmania from Peru and Nepal to miltefosine","volume":"73","author":"Yardley","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib33","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","article-title":"Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1111\/j.1469-0691.2011.03630.x_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005067.pub3","article-title":"Interventions for Old World cutaneous leishmaniasis","author":"Gonzalez","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaad.2010.04.014","article-title":"Superior efficacy of oral fluconazole 400\u2003mg daily versus oral fluconazole 200\u2003mg daily in the treatment of cutaneousLeishmania major infection: a randomized clinical trial","volume":"64","author":"Emad","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1111\/j.1469-0691.2011.03630.x_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004834.pub2","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","author":"Gonzalez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib37","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1371\/journal.pntd.0000491","article-title":"First\u2010line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony","volume":"3","author":"Miranda\u2010Verastegui","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0035-9203(03)90093-9","article-title":"Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990\u201399","volume":"97","author":"Convit","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-9292-6-3","article-title":"Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13\u201315 June, 2006","volume":"6","author":"Modabber","year":"2007","journal-title":"Kinetoplastid Biol Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib40","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1086\/655134","article-title":"Designing and reporting clinical trials on treatments for cutaneous leishmaniasis","volume":"51","author":"Gonzalez","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0035-9203(97)90404-1","article-title":"Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with ambisome","volume":"91","author":"Nonata","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4269\/ajtmh.2009.81.387","article-title":"Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia","volume":"81","author":"Soto","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib44","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1128\/AAC.43.12.2910","article-title":"Efficacy of the triazole sch 56592 againstLeishmania amazonensis andLeishmania donovani in experimental murine cutaneous and visceral leishmaniases","volume":"43","author":"Al\u2010Abdely","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib45","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1128\/AAC.01498-10","article-title":"Successful treatment of old world cutaneous leishmaniasis due toL. infantum with posaconazole","volume":"55","author":"Paniz Mondolfi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1211\/jpp.59.1.0006","article-title":"Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis","volume":"59","author":"Garnier","year":"2007","journal-title":"J Pharm Pharmacol"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib47","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dkm303","article-title":"In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs","volume":"60","author":"Garnier","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2011.03630.x_bib48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The relationship between leishmaniasis and aids: the second 10\u2003years","volume":"21","author":"Alvar","year":"2008","journal-title":"Clin Microbiol Rev"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14618620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14618620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T19:05:06Z","timestamp":1560366306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14618620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1198743X14618620"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03630.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}